Univest
Univest
  • Markets

J.B. Chemicals and Pharmaceuticals Stock Prediction 2026: Analyst Target, Forecast and Key Levels

  • June 22, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

NSE: JBCHEPHARM | CMP Rs 2212.5. 52W High Rs 2300.0. 52W Low Rs 1580.03. Base target Rs 2544.4. Bull case Rs 2832.0.

The J.B. Chemicals and Pharmaceuticals stock prediction for 2026 points to a base case target of Rs 2544.4, with a bull case of Rs 2832.0 and a bear case of Rs 2035.5 based on current fundamentals and sector outlook. J.B. Chemicals and Pharmaceuticals is currently trading at Rs 2212.5 on the NSE, and analysts are closely tracking its trajectory against the Nifty 50 and Sensex.

This article covers the J.B. Chemicals and Pharmaceuticals stock prediction in detail, including short-term, 12-month, and long-term views, key business drivers, risk factors, and the bull-bear scenario framework that Kunal Singla and Ankit Jaiswal use to evaluate the stock’s risk-reward.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Analyst Target Summary for J.B. Chemicals and Pharmaceuticals Stock Prediction 2026
  • J.B. Chemicals and Pharmaceuticals Company Overview
  • J.B. Chemicals and Pharmaceuticals Stock Prediction Across Time Horizons
    • Short-Term J.B. Chemicals and Pharmaceuticals Stock Prediction for 3 to 6 Months
    • 12-Month J.B. Chemicals and Pharmaceuticals Stock Prediction for 2026
    • Long-Term J.B. Chemicals and Pharmaceuticals Stock Prediction for FY27 to FY28
  • Key Factors Driving the J.B. Chemicals and Pharmaceuticals Stock Prediction 2026
    • US Generics Pipeline and ANDA Approvals
    • Domestic Formulations Growth
    • API Integration and Cost Efficiency
    • Emerging Market Expansion
  • Bull Case and Bear Case for J.B. Chemicals and Pharmaceuticals Stock Prediction 2026
  • Reading the J.B. Chemicals and Pharmaceuticals Stock Prediction from Analyst Perspective
  • Key Risks to the J.B. Chemicals and Pharmaceuticals Stock Prediction 2026
    • US FDA Warning Letters and Import Alerts
    • Pricing Pressure in US Generics
    • Regulatory and Drug Price Control Orders
    • Raw Material and API Price Volatility
  • How to Monitor the J.B. Chemicals and Pharmaceuticals Stock Prediction
  • Conclusion
  • Frequently Asked Questions on J.B. Chemicals and Pharmaceuticals Stock Prediction 2026
    • What is the J.B. Chemicals and Pharmaceuticals stock prediction for 2026?
    • What is the 12-month J.B. Chemicals and Pharmaceuticals stock forecast?
    • What is the J.B. Chemicals and Pharmaceuticals share price target for FY27 and FY28?
    • What are the key risks to the J.B. Chemicals and Pharmaceuticals stock prediction?
    • Is J.B. Chemicals and Pharmaceuticals a good stock to buy in 2026?
    • What is the J.B. Chemicals and Pharmaceuticals 52-week high and low?
    • How do I track the J.B. Chemicals and Pharmaceuticals stock prediction?

Analyst Target Summary for J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

Parameter Details
NSE Symbol JBCHEPHARM
Company J.B. Chemicals and Pharmaceuticals
Sector Pharma
CMP (Rs) 2212.5
52-Week High (Rs) 2300.0
52-Week Low (Rs) 1580.03
Market Cap N/A
P/E Ratio N/A
Base Target 12M (Rs) 2544.4
Bull Case (Rs) 2832.0
Bear Case (Rs) 2035.5

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.

  • Discover stocks investors are actively accumulating
  • High-conviction opportunities backed by research
  • Designed for the next phase of market growth

Unlock the latest Top Stock Picks on Univest

See the Stocks →

J.B. Chemicals and Pharmaceuticals Company Overview

J.B. Chemicals and Pharmaceuticals (NSE: JBCHEPHARM) is a pharma-sector company listed on the National Stock Exchange of India. The company operates in the pharma space and has established a presence in its respective market through its products and services. Understanding the business model is essential before analysing the J.B. Chemicals and Pharmaceuticals stock prediction.

The stock is tracked by retail and institutional investors who monitor the Nifty Pharma for sector-level cues. With a current market price of Rs 2212.5 and a 52-week range of Rs 1580.03 to Rs 2300.0, J.B. Chemicals and Pharmaceuticals presents a case study in pharma sector dynamics and valuation.

J.B. Chemicals and Pharmaceuticals Stock Prediction Across Time Horizons

Short-Term J.B. Chemicals and Pharmaceuticals Stock Prediction for 3 to 6 Months

In the short term, near-term earnings delivery and broader market sentiment. Kunal Singla notes that Rs 2345.2 is a realistic near-term target if earnings momentum holds and FII flows remain supportive of the broader Nifty 50 trajectory.

12-Month J.B. Chemicals and Pharmaceuticals Stock Prediction for 2026

The 12-month J.B. Chemicals and Pharmaceuticals stock prediction stands at Rs 2544.4 as the base case, representing roughly 15% upside from the current market price. This target is contingent on sustained earnings growth, margin improvement, and a stable macro backdrop through 2026.

Long-Term J.B. Chemicals and Pharmaceuticals Stock Prediction for FY27 to FY28

Ankit Jaiswal observes that if the company executes on its strategic roadmap, the long-term share price target points toward Rs 3097.5 by FY28, assuming compounding earnings growth and a potential sector multiple re-rating.

Key Factors Driving the J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

US Generics Pipeline and ANDA Approvals

A strong pipeline of abbreviated new drug applications (ANDAs) with the US FDA creates medium-term revenue opportunity. Each new approval adds predictable, high-margin generic revenue streams. Kunal Singla watches this factor closely when forming the 2026 share price view.

Domestic Formulations Growth

India’s branded generics market is expanding on the back of rising health insurance penetration and chronic disease burden. Strong domestic volume growth supports revenue stability. Ankit Jaiswal watches this factor closely when forming the 2026 share price view.

API Integration and Cost Efficiency

Backward integration into active pharmaceutical ingredients reduces input cost volatility and improves gross margins. In-house API supply insulates the company from Chinese raw material price shocks. Kunal Singla watches this factor closely when forming the 2026 share price view.

Emerging Market Expansion

Scaling up in underpenetrated markets across Africa, Latin America, and Southeast Asia diversifies revenue away from the highly competitive US generics segment. Ankit Jaiswal watches this factor closely when forming the 2026 share price view.

Bull Case and Bear Case for J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

Scenario Target (Rs) Key Condition
Bull Case 2832.0 Strong earnings beat, sector tailwinds, FII inflows
Base Case 2544.4 In-line earnings, stable macro, 15% upside
Bear Case 2035.5 Earnings miss, sector headwinds, risk-off markets

These scenarios are illustrative and based on broad analyst estimates. They are not a guaranteed return forecast from Univest.

Reading the J.B. Chemicals and Pharmaceuticals Stock Prediction from Analyst Perspective

Kunal Singla notes that the J.B. Chemicals and Pharmaceuticals stock prediction hinges on the company’s ability to maintain earnings growth while managing sector-specific headwinds. The current valuation, with the stock at Rs 2212.5, offers a reasonable entry point for investors with a 12 to 24 month horizon.

Ankit Jaiswal observes that investors should track quarterly earnings delivery, management commentary on the demand environment, and movement in the Nifty Pharma before assigning high conviction to the share price forecast. Both analysts suggest that risk management is as important as upside in any stock view.

Key Risks to the J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

US FDA Warning Letters and Import Alerts

Any USFDA observations, import alert, or warning letter at manufacturing facilities can block US shipments and severely impact revenue in the near term. Investors should factor this risk into the 2026 outlook.

Pricing Pressure in US Generics

Structural price erosion in the US generics market, driven by customer consolidation and competition, compresses per-unit realisations year on year. Investors should factor this risk into the 2026 outlook.

Regulatory and Drug Price Control Orders

The Indian government periodically brings more drugs under DPCO price caps, which can cap domestic price increases and squeeze branded formulation margins. Investors should factor this risk into the 2026 outlook.

Raw Material and API Price Volatility

Dependence on Chinese API inputs creates supply chain vulnerability. Any disruption or cost spike in raw materials directly squeezes gross margins. Investors should factor this risk into the 2026 outlook.

How to Monitor the J.B. Chemicals and Pharmaceuticals Stock Prediction

To stay updated on the J.B. Chemicals and Pharmaceuticals stock prediction and track real-time price movements and fundamentals, investors can use verified data platforms.

Use the Univest Screener to track J.B. Chemicals and Pharmaceuticals live price and updated target levels.

Key data points to monitor include quarterly results, promoter shareholding changes, FII and DII flow data, and movement in the Nifty 50 which sets the broad market tone for share prices broadly.

Conclusion

The J.B. Chemicals and Pharmaceuticals stock prediction for 2026 presents a base case of Rs 2544.4, a bull case of Rs 2832.0, and a bear case of Rs 2035.5. These targets are derived from sector fundamentals, earnings trajectory, and macro tailwinds that Kunal Singla and Ankit Jaiswal track across the pharma space.

Investors looking for the best share price target for 2026 should review quarterly earnings, study the bull and bear scenario table, and consult a SEBI-registered advisor before making investment decisions based on any stock prediction.

Download the Univest iOS App or Univest Android App to track J.B. Chemicals and Pharmaceuticals share price live and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on J.B. Chemicals and Pharmaceuticals Stock Prediction 2026

What is the J.B. Chemicals and Pharmaceuticals stock prediction for 2026?

Ans. The J.B. Chemicals and Pharmaceuticals stock prediction for 2026 is a base case of Rs 2544.4, a bull case of Rs 2832.0, and a bear case of Rs 2035.5 based on sector fundamentals and earnings outlook.

What is the 12-month J.B. Chemicals and Pharmaceuticals stock forecast?

Ans. The 12-month J.B. Chemicals and Pharmaceuticals stock forecast is Rs 2544.4, representing approximately 15% upside from the current market price. This J.B. Chemicals and Pharmaceuticals stock prediction assumes in-line earnings and stable macro conditions through 2026.

What is the J.B. Chemicals and Pharmaceuticals share price target for FY27 and FY28?

Ans. The long-term J.B. Chemicals and Pharmaceuticals stock prediction suggests Rs 3097.5 by FY28, contingent on sustained earnings growth and a potential sector re-rating. This is a J.B. Chemicals and Pharmaceuticals stock forecast, not a guaranteed return.

What are the key risks to the J.B. Chemicals and Pharmaceuticals stock prediction?

Ans. Key risks to the J.B. Chemicals and Pharmaceuticals stock prediction include sector-specific headwinds, FII selling pressure, earnings misses relative to expectations, global macro uncertainty, and regulatory changes. Investors should factor these risks into their assessment of any J.B. Chemicals and Pharmaceuticals stock forecast.

Is J.B. Chemicals and Pharmaceuticals a good stock to buy in 2026?

Ans. Whether J.B. Chemicals and Pharmaceuticals is a good stock to buy depends on your investment horizon and risk tolerance. The J.B. Chemicals and Pharmaceuticals stock prediction of Rs 2544.4 implies potential upside. Consult a SEBI-registered advisor before investing based on any J.B. Chemicals and Pharmaceuticals stock forecast.

What is the J.B. Chemicals and Pharmaceuticals 52-week high and low?

Ans. The J.B. Chemicals and Pharmaceuticals 52-week high is Rs 2300.0 and the 52-week low is Rs 1580.03. These levels serve as key reference points when evaluating the J.B. Chemicals and Pharmaceuticals stock prediction.

How do I track the J.B. Chemicals and Pharmaceuticals stock prediction?

Ans. You can track the J.B. Chemicals and Pharmaceuticals stock prediction on the Univest Screener at screeners.univest.in, which provides real-time price data, analyst targets, and fundamental metrics. Verify all price data with the official NSE website before acting on any J.B. Chemicals and Pharmaceuticals stock forecast.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply